2024-03-28T18:52:25Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/852452022-11-17T02:08:08Zhdl_2115_20043hdl_2115_137High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease1000000645905Shiratori, Souichi1000020845284Ohigashi, HiroyukiAra, Takahide1000090769887Yasumoto, Atsushi1000070759290Goto, Hideki1000080435859Nakagawa, MasaoSugita, Junichi1000070455632Onozawa, MasahiroKahata, KaoruEndo, Tomoyuki1000020419576Hashimoto, Daigo1000040284096Teshima, Takanoriopen accessThis is a post-peer-review, pre-copyedit version of an article published in Annals of Hematology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00277-020-04347-1Allogeneic hematopoietic stem cell transplantationPeripheral blood stem cell transplantationAntithymocyte globulinGraft-versus-host diseaseAbsolute lymphocyte count490Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 x 10(9)/L vs 0.06 x 10(9)/L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (>= 0.15 x 10(9)/L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC before ATG is a risk factor for SC-aGVHD.Springer2021-05engjournal articleAMhttp://hdl.handle.net/2115/85245https://doi.org/10.1007/s00277-020-04347-10939-5555Annals of hematology100513211328https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/85245/2/ATG%20%28Lym%29%20Sup%20Fig1.JPGimage/jpeg81.88 KB2021-05https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/85245/3/ATG%20%28Lym%29%20Sup%20Fig2.jpgimage/jpeg63.03 KB2021-05https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/85245/1/Annals%20of%20Hematology_s00277-020-04347-1.pdfapplication/pdf444.81 KB2021-05